Systematic Review and Metanalysis of Oncomarkers in IPF Patients and Serial Changes of Oncomarkers in a Prospective Italian Real-Life Case Series.
idiopathic pulmonary fibrosis
lung cancer
oncomarker
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
31 Jan 2021
31 Jan 2021
Historique:
received:
30
12
2020
revised:
24
01
2021
accepted:
28
01
2021
entrez:
12
2
2021
pubmed:
13
2
2021
medline:
13
2
2021
Statut:
epublish
Résumé
Idiopathic pulmonary fibrosis (IPF) is a severe progressive interstitial lung disease. At 5-year follow-up, 15% of IPF patients develop lung cancer, which significantly reduces the survival rate. Here we review the literature on the clinical role of oncomarkers in IPF progression, and describe the trend of routine oncomarkers in IPF patients over the longest follow-up yet reported. A systematic search of the literature in PubMed was performed to find relevant studies published up to 24 September 2020. The most common oncomarkers were chosen to select papers related to pulmonary fibrosis. Then, 24 IPF patients and 25 non-IPF patients, followed at Careggi ILD Referral Centre and Siena Regional Referral Centre for ILD, were enrolled consecutively. A few studies reported an association between serum oncomarkers and severity of IPF. NSE, CEA, Ca19.9, and Ca125 were higher in the IPF, than in the non-IPF, group at every follow-up ( This study focused on the discovery of multiple biomarker signatures, such as combinations of oncomarkers, that are widely and routinely available in biochemistry laboratories. The combination of clinical parameters and biological markers could help achieve more accurate results regarding prognosis and response to treatment in IPF. Our results could pave the way for a more "personalized" medical approach to patients affected by IPF.
Sections du résumé
BACKGROUND
BACKGROUND
Idiopathic pulmonary fibrosis (IPF) is a severe progressive interstitial lung disease. At 5-year follow-up, 15% of IPF patients develop lung cancer, which significantly reduces the survival rate. Here we review the literature on the clinical role of oncomarkers in IPF progression, and describe the trend of routine oncomarkers in IPF patients over the longest follow-up yet reported.
MATERIALS AND METHODS
METHODS
A systematic search of the literature in PubMed was performed to find relevant studies published up to 24 September 2020. The most common oncomarkers were chosen to select papers related to pulmonary fibrosis. Then, 24 IPF patients and 25 non-IPF patients, followed at Careggi ILD Referral Centre and Siena Regional Referral Centre for ILD, were enrolled consecutively.
RESULTS
RESULTS
A few studies reported an association between serum oncomarkers and severity of IPF. NSE, CEA, Ca19.9, and Ca125 were higher in the IPF, than in the non-IPF, group at every follow-up (
CONCLUSIONS
CONCLUSIONS
This study focused on the discovery of multiple biomarker signatures, such as combinations of oncomarkers, that are widely and routinely available in biochemistry laboratories. The combination of clinical parameters and biological markers could help achieve more accurate results regarding prognosis and response to treatment in IPF. Our results could pave the way for a more "personalized" medical approach to patients affected by IPF.
Identifiants
pubmed: 33572642
pii: cancers13030539
doi: 10.3390/cancers13030539
pmc: PMC7867006
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
J Clin Lab Anal. 2007;21(2):103-6
pubmed: 17385665
Respir Physiol Neurobiol. 2009 Jul 31;167(3):261-7
pubmed: 19464392
Respirology. 2014 Jul;19(5):707-13
pubmed: 24903079
Respir Med. 2007 Oct;101(10):2176-81
pubmed: 17631992
Inflammation. 2014 Feb;37(1):10-6
pubmed: 23912648
Clin Respir J. 2017 May;11(3):337-345
pubmed: 26077281
Clin Respir J. 2018 Apr;12(4):1700-1705
pubmed: 29094803
Respirology. 2020 Dec 17;:
pubmed: 33336433
Nan Fang Yi Ke Da Xue Xue Bao. 2020 Jul 30;40(7):1062-1065
pubmed: 32895164
Clin Exp Med. 2019 Nov;19(4):487-494
pubmed: 31485847
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620906326
pubmed: 32066332
Respirology. 1998 Sep;3(3):199-202
pubmed: 9767620
Am J Respir Crit Care Med. 2016 Nov 15;194(10):1242-1251
pubmed: 27149370
PLoS Med. 2008 Apr 29;5(4):e93
pubmed: 18447576
Sarcoidosis Vasc Diffuse Lung Dis. 2009 Jul;26(1):54-63
pubmed: 19960789
Chest. 2012 Apr;141(4):1047-1054
pubmed: 21940773
Eur J Clin Invest. 2020 Apr 20;:e13242
pubmed: 32307698
Lung. 2000;178(3):171-9
pubmed: 10871435
Respir Investig. 2019 Sep;57(5):430-434
pubmed: 31031123
ERJ Open Res. 2018 Feb 02;4(1):
pubmed: 29410958
Multidiscip Respir Med. 2012 Nov 12;7(1):42
pubmed: 23146172
Chron Respir Dis. 2020 Jan-Dec;17:1479973120958428
pubmed: 32969271
Respirology. 2012 Nov;17(8):1247-52
pubmed: 22816375
Respirology. 2002 Mar;7(1):15-21
pubmed: 11896896
Immunol Res. 2020 Dec;68(6):414-421
pubmed: 33089426
J Clin Immunol. 2013 Jan;33(1):264-70
pubmed: 22878841
PLoS One. 2017 Mar 29;12(3):e0174547
pubmed: 28355256
Respir Investig. 2020 Jan;58(1):21-27
pubmed: 31708467
Sarcoidosis Vasc Diffuse Lung Dis. 2015 Sep 14;32(3):228-36
pubmed: 26422568
Histol Histopathol. 1996 Apr;11(2):463-83
pubmed: 8861769
Sarcoidosis Vasc Diffuse Lung Dis. 2015 Aug 03;32 Suppl 1:17-23
pubmed: 26237439
Biomark Med. 2020 Jun;14(8):665-674
pubmed: 32613855
Scand J Clin Lab Invest. 2008;68(6):479-83
pubmed: 18609101
Respiration. 2020;99(3):207-212
pubmed: 32114588
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753
Respiration. 2008;76(2):234-8
pubmed: 18487875
J Appl Physiol (1985). 2021 Jan 14;:
pubmed: 33444119
J Exp Med. 2011 Jul 4;208(7):1339-50
pubmed: 21727191
Sarcoidosis Vasc Diffuse Lung Dis. 2010 Jul;27(2):138-46
pubmed: 21319596
Proteomics Clin Appl. 2014 Dec;8(11-12):932-50
pubmed: 25169739
Lancet Respir Med. 2017 Dec;5(12):946-955
pubmed: 29150411
Respiration. 2007;74(5):548-52
pubmed: 17347558
Clin Exp Med. 2020 May;20(2):207-216
pubmed: 31970550